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1. Introduction 
After the discovery of streptomycin (SM) and isonicotinic acid hydrazide (INH), the number 
of tuberculosis (TB) patient dramatically decreased. People believed that TB was already a 
past-disease. However, World Health Organization (WHO) reported that there were an 
estimated 9.4 million incident cases of TB globally in 2009, which is equivalent to 137 cases 
per 100 000 population (World Health Organization, 2010). There are huge difference in 
perception of TB and the actual situation of TB. The reason for the misunderstanding of 
current status of TB could come from low rate of TB crisis. After infection with TB, only 5 % 
people develop the disease within 1~2 year, and 5 % of the remaining develop within their 
life time. Fortunately, mot people live their life without crisis of TB (Koul et al., 2011).  
The typical treatment of TB is now proposed by WHO. The protocol is named as direct 
observation treatment short course (DOTS), but the period of treatment is not “short”. The 
period is at least 6 months, which is not “short” compared to the therapeutic period using 
antibiotics against common infectious diseases. Although, the regimen of TB treatment is the 
most powerful chemotherapy in the world. 
In 2006, we were surprised to hear of the outbreak in South Africa (Cohen, 2006). The case 
reports recall the worst event, “Spanish Flu”, in 18th century. The name of TB hailed around 
the world due to the emergence of extremely multi-drug resistance TB (XDR-TB) which 
caused the abnormally rapid death of human immunodeficiency virus (HIV)-positive 
patients suffering from XDR-TB (Koenig, 2008). The life time of TB patients without 
chemotherapy is usually more than 2 years, but in the case of the HIV-positive XDR-TB 
patient, their lifetimes were within 1 month, like “Spanish Flu”. We feared the out break of 
“New Type TB” in the World. Subsequently, TB cases classified under XDR-TB had already 
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spread around the world. Many investigations suggest that the incredible virulence of XDR-
TB could depend on the status of health condition of patient, that is, those having acquired 
immunodeficiency syndrome (AIDS) or not. This event, “South African Shock”, gave us a 
warning that continuous development of new TB drugs is needed. 
The development of strong medicines against TB has progressed at a snail's pace since 
1970’s (Ma et al., 2010). The derivatives or analogs of currently used TB drugs faced the 
problem of cross resistance to formerly developed drugs. It is obvious, because these kinds 
of drug share the same or similar targets, hence, the similar mechanism of escaping from the 
attack of antibiotics is observed. Therefore, development of “New Face Drug against TB” is 
strongly desired.  
2. Discovery of sugar derivatives as anti-tubercular compounds 
2.1 Background  
The genus Mycobacterium belongs to actinobacteria and consists of mycobacteriaceae 
including pathogenic pieces Mycobacterium tuberculosis and Mycobacterium leprae 
(Goodfellow & Mage, 1998). The meanings of Latin prefix “myco” is “fungus” and also 
“wax”. The cell wall contains huge amount of waxy compounds, of which weight is around 
60 % of dried bacilli (Rao & Meena, 2011). The cell wall also consists of peptidoglycan which 
binds to arabinogalactan chains. Mycobacterium species have unique immunogenic sugar 
lipids compounds in their cell walls, such as trehalose-6,6'-dimycolate (TDM), alias name is 
cord factor, etc. (Berg et al., 2007; Ryll et al., 2001; Kaur et al, 2009)  Trehalose is a natural 
alpha-linked disaccharide formed by an ǂ,ǂ-1,1-glucoside bond between two ǂ-glucose 
units, which is seen in cell wall of fungi, plants and bacteria(Nehls, 2008). It has high water 
retention capabilities implicating in anhydrobiosis (Kaushik & Bhat, 2003). Arabinose is 
synthesized from phosphoribosyl pyrophosphate (pRpp) derived from glucose through 
hexose monophosphate shunt and used as a substrate of arabinobgalactan (AG) structure in 
Mycobacterium (Crick et al., 2004). Decaprenyl phosphate is transferred to pRpp by a 
transferase, and forms 5-phospho-decaprenylphospho-ribose (5-pDpR).  5-pDpR is 
dephosphorylated, and become DpR. DpR is changed to decaprenyl arabinose (DpA) by an 
epimerase, and then DpA is transferred to AG by an arabinosyltransferase. Recently, the 
arabinose synthesis pathway is receiving plenty of attention as new drug target of 
developing new TB drugs (Wolucka, 2008; Manina, 2010). Ethambutol (EB), a first line TB 
drug, shows the anti-tubercular activity by inhibiting Emb enzymes in mycobacteria. 
Recently, Besra et al. indicated that EB bind to the C-terminal region of EmbC (Alderwick et 
al., 2011). The single knockout of EmbC and EmbB was lethal in M. tuberculosis, but not in M. 
smegmatis and Corynebacterium glutamicum (Amin et al., 2008; Goude et al., 2008). Thus, these 
enzymes and the structure catalyzed by Emb enzymes are crucial to M. tuberculosis.  
As seen above, carbohydrate moieties are crucial for the bacilli. So, we expect any damage 
on the sugar containing structures could destroy the bacilli, we have searched the anti-
tubercular activity with random screening method from the sugar based chemical libraries. 
The library consisted of various substrates and donors of which the sugar chains were 
modified. After screening more than 200 compounds, 2 compounds showed the positive 
results.  
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2.2 OCT359, allyl-O-(2,3,4,6-tetra-O-acetyl--D-galactopyranosyl)-(1->6)-O-(2,3,4-tri-O- 
acetyl--D-galactopyranosyl)-(1->6)-O-2,3,4-tri-O-acetylb-D-glucopyranoside 
One of the sugar compounds is OCT359 which is obtained from a plant root, Stachys sieboldi 
Miq (Chiba et al., 2007). The plant root possess huge amount of tetrasaccharide, stachyose, 
consisting of two ǂ-D-galactose units, one ǂ-D-glucose unit, and one ǃ-D-fructose unit 
sequentially linked as gal(ǂ1→6)gal(ǂ1→6)glc(ǂ1↔2ǃ)fru. The name stachyose is originated 
from the name of the species, Stachys sieboldi Miq.  OCT359, allyl-O-(2,3,4,6-tetra-O-acetyl--
D-galactopyranosyl)-(1->6)-O-(2,3,4-tri-O-acetyl--D-galactopyranosyl)-(1->6)-O-2,3,4-tri-O-
acetylb-D-glucopyranoside, is obtained when stachyose is hydrolyzed and acetylated. The 
minimum inhibitory concentration (MIC) of OCT359 to M. tuberculosis is 3.13 g/ml. It is 
comparable to the MICs of aminoglycoside antibiotics, such as streptomycin and 
kanamycin, and amycacin. OCT359 is effective not only against M. tuberculosis, but also 
Mycobacterium avium, Staphylococcus aureus including MRSA. However, OCT359 is not 
effective to Escherichia coli. So, the antibacterial spectrum of OCT359 seems to be limited to 
gram-positive bacilli. The structure is very unique and not observed in the cell wall of the 
bacilli.  It would be difficult to use the compound as a substrate to synthesize cell wall 
components. Hydrophobic property of the compound is critical to show the activity. Other 
mechanism by which the compound, inhibit bacterial metabolisms, is by inhibiting enzymes 
in the cell and waxy cell walls, because all hydroxyl groups of OCT359 are acetylated. The 
mechanism of antibacterial activity of OCT359 has not been elucidated sufficiently. Our 
preliminary data suggested that OCT359 includes metal molecules and work as inclusion 
compound. OCT359 is effective to drug resistant bacilli, MDR-TB and MRSA, therefore, it 
could be potential novel compound for TB drugs. 
2.3 OCT313, 2-acetamide-2-deoxy--D-glucopyranosyl N,N-dimethyldithiocarbamate 
Another sugar derivative, OCT313 (Horita et al., 2009); 2-acet-amido-2-deoxy--D-
glucopyranosyl N,N-dimethyldithiocarbamate (DMDC), is the derivative of N-acetyl-D-
glucosamine (GlcNAc), which is a monosaccharide derivative of glucose. GlcNAc is 
significantly available in several biological systems (Moussian, 2008). Peptidoglycan in a 
bacterial cell wall consists of GlcNAc and N-acetylmuramic acid (MurNAc), cross-linked with 
oligopeptides at the lactic acid residue of MurNAc (van Heijenoort, 2001). OCT313, GlcNAc-
DMDC, shows the antibacterial activity to slow growing Mycobacterium species, M. tuberculosis 
and M. bovis, however, weak activity to other Mycobacterium species, Mycobacterium avium and 
Mycobacterium smegmatis.  Furthermore, OCT313 does not show the antibacterial activity to S. 
aureus and E. coli. This character is favorable to use for TB therapy.  
As the bacteriolytic effect of OCT313 on the bacilli is observed, the first mode of action of 
OCT313 is a cell wall of M. tuberculosis. OCT313 also have bactericidal activity. The 
dithiocarbamate group at C-1 position of the glucopyranoside ring of OCT313 was requisite 
for the antibacterial activity, and N-acetylation is also required to show the activity. The 
substitution of dithiocarbamate lead to loss of antibacterial activity and dithiocarbamate 
exhibits the antibacterial activity.  Thus, the main body of the activity is dithiocarbamate. 
The acetyl group at C-2 of OCT313 was substituted by, either propyl, butyl, benzyl or oleic 
acid groups. According to a length of the fatty acid chain, the antibacterial effect changes. 
So, acetyl group is optimum as a carbon chain at C-2 position. The meaning of N-acetylation 
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to the antibacterial activity of OCT313 is not still clear. It may be involved in the localization 
of the compound in the cell wall of the bacilli by changing the liquid phase of the compound 
from hydrophobic to hydrophilic.  
In order to investigate the target of OCT313 on the bacilli, the drug resistant clones were 
made. During the production of the resistant clones, it was revealed that the production of 
drug resistance to OCT313 is very low, 10-7. This character is very important to prevent from 
the emerging drug resistant clones during the therapy. The precise targets of OCT313 on the 
bacilli are now under investigation. OCT313 is effective to MDR-TB clinical isolates to the 
same extent as the drug susceptible TB clinical isolates. There is no cross resistance of 
OCT313 with other currently used TB drugs. As the TB regimen includes more than two 
drugs which have different modes of antibacterial actions, this character is very important 
when developing new drugs.  
A dithiocarbamate is an analog of carbamate in which both oxygen atoms are replaced by 
sulfur atoms. The primary and secondary amines react with carbon disulfide to form 
dithiocarbamates. One of characters of dithiocarbamates is ligands for chelating metals 
(Jones et al., 1980). Dithiocarbamates readily forms complex with many metal salts such as 
copper, ferrous, ferric, cobaltous, and nickel salts. The diethyldithiocarbamate ion chelates 
to metals via the two sulfur atoms. Oxidation of sodium diethyldithiocarbamate gives the 
disulfide, also called a tetraethylthiuram disulfide (Dalvi, 1988), which is marketed as an 
anti-alcoholism drug labeled as Antabuse and Disulfiram (Barth & Malcolm, 2010). Other 
more complicated bonding modes of dithiocarbamates are known to be a unidentate ligand 
and a bridging ligand using one or both sulfur atoms. The carbon length of dithiocarbamate 
at C-1 position of OCT313 was changed, and then, the effect of these synthesized 
compounds on the antibacterial activity was investigated. Methyl group has most strong 
activity among them. The target of OCT313 is not yet clear, however, the activities of 
binding to enzymes and/or chelating metals could be critical to show the anti-mycobacterial 
activities.    
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Fig. 1. Dithiocarbamate sugar derivatives. A: OCT313; 2-acetamide-2-deoxy--D-
glucopyranosyl N,N-dimethyldithiocarbamate,  B: OCT313HK: 2-acetamido-2-deoxy--D-
glucopyranosyl pyrrolidine-1-carbodithioate. 
The advantages of sugar conjugating dithiocarbamates are reducing their toxicity and 
making narrow anti-bacterial spectrum. We have previously analyzed the toxicity of 
dimethyldithiocarbamate (DMDC) and its sugar derivative, OCT313. The toxicity of OCT313 
to human cell lines was 100 times lesser than that of DMDC. Furthermore, our unpublished 
data indicate that administration of OCT313 to mice was not toxic and tolerable to inhibition 
of cholinesterase, which is mostly known to be side effect of carbamate compounds (Thorn, 
1967). 
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In summary, the derivative of N-acetyl glucosamine, OCT313, could be new drug target of 
MTB and low frequency of emerging drug resistance. The procedure of sugar conjugating 
compounds is useful to reduce their toxicity.   
2.4 OCT313HK, 2-acetamido-2-deoxy--D-glucopyranosyl pyrrolidine-1-carbodithioate 
Dimethyldithiocarbamate (DMDC), a functional moiety of OCT313 at C-1 is revealed to be 
critical for the anti-mycobacterial activity (Horita et al, 2009). The bactericidal and fungicidal 
effects of dihiocarbamate and thiuram disulfide were patented by Tisdale and Williams in 
1934 (Wilson & Fishbein, 1972). Many studies have revealed that the antimicrobial activities 
of DMDC and diethyldithiocarbamate (DDC) since 1942 (Gordon, 1942; van Raalte, 1952; 
Thorn & Ludwig, 1962).  DMDC has the antifungal activity to Fusarium roseum by inhibiting 
oxidation pathway of -keto-glutamic acid, because the augmentation of -keto-glutamic 
acid in the fungus was observed by treatment of ferric dimethyldithiocarbamate (Ferbam) 
(Sisler & Marshall, 1957). The drug targets of DMDC or DDC in Penicillium, and Aspergillus 
were suggested to be the enzymes at oxidation pathway of -keto-glutamic acid or pyruvate 
pathway coupling with -lipo acids or acetyl-CoA, since the augmentation of pyruvate in 
the organisms was observed by the treatment of DMDC or DDC (Kaars & Van der Kerk, 
1956). Intriguingly, zinc dimethyldithiocarbamate (Ziram) is able to inhibit the metabolic 
pathway of keto-acid, however, does not affect the synthesis or metabolic pathway of citric 
acid (Dimond et al., 1941). Furthermore, thiuram, tetramethylthirum disulfide, which is 
dimer of DMDC, has strong growth inhibitory activity to yeast under anaerobic 
environment (Manten, 1950). This mode of action of dithiocarbamates is considered to be an 
inhibition of respiratory chain in yeast. DMDC was also reported to have a growth 
inhibitory activity on Saccharomyces cerevisiae by inhibiting a synthesis of acetyl-CoA 
(GoksØyr, 1955). These data suggest that dithiocarbamates can inhibit different metabolic 
pathways in each organism. The precise target of dithiocarbamates on mycobacterium is not 
been revealed until the present. 
Many studies of physiological activities of dithiocarbamates in mammals and human were 
reported (Taylor et al., 1987; Shah et al., 1997; Kang et al., 2008). And the effects of them 
against pathogenic bacteria, fungi and parasite were also reported (Erol et al., 1995; Cascio et 
al., 1996; Adachi et al., 1997; Nagano et al., 1997; Ohtake et al., 1998; Le Quellec et al., 1996; 
Weuffen et al., 1967a, 1967b). Majority of the predictable targets of dithiocarbamates against 
these organisms is considered to inhibit metal containing enzymes by their activities of 
chelating metals or enzymes by bind covalently to thiol group of cysteine residues (Taylor et 
al., 1987; Shah et al., 1997; Kang et al., 2008). Structure-activity-related studies of 
dithiocarbamate against bacteria were reported (Chabrier et al., 1956; Miller & Elson, 1949). 
When dithiocarbamates were written as X(Y)NCS2M (X=hydrogen or alkyl, Y=hydrogen, 
alkyl or aryl, M=metallic in nature), the strong order of antibacterial activity at X(Y)N 
position was piperizyl>(CH3)2N>morpholinyl. (CH3)2N also had anti-fungal activity. 
In the 1950’s, the effect of dithiocarbamates on Mycobacterium was reported (Liebermeister, 
1950; Schraufstätter, 1950; Garattini & Leonardi, 1955; Jeney & Zsolnai, 1956). Recently, 
Makarov et al. and Byrne et al. reported that DDC and pyridine dithiocarbamate (PDTC) had 
anti-tuberculosis activity against dormant stage of M. tuberculosis (Makarov et al., 2006; Byrne 
et al., 2007). In order to improve the activity of OCT313 (GlcNAc-DMDC), DMDC at C-1 
position of OCT313 was substituted by PDTC, which was designated as OCT313HK (GlcNAc-
PDTC) (Horita et al., 2011). The MIC of OCT313HK against M. tuberculosis became 4 times 
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lower than that of OCT313. Interestingly, antibacterial spectrum of PDTC became narrow by 
conjugating with GlcNAc. The antibacterial activity of OCT313HK is specific to slow growing 
Mycobacterium, such as Mycobacterium bovis and M. tuberculosis, but not to Mycobacterium avium 
and Mycobacterium smegmatis. OCT313HK is not effective to Escherichia coli and Staphylococcus 
aureus. Furthermore, those compounds have bactericidal and bacteriolytic activity to the 
bacilli. The analysis of the resistance clones of BCG for OCT313 and OCT313HK predict that 
the first mode of action of those compounds is a cell wall of the bacilli. Our preliminary 
experiment showed that OCT313 and OCT313HK can inhibit mycobacterial enzyme involved 
in the cell wall synthesis, however, DMDC and PDTC have different mechanisms. These data 
suggest that sugar conjugated dithiocarbamate have different targets of inhibition on cell wall 
consisting enzymes in mycobacteria from dithiocarbamate.  
In summary, GlcNAc conjugated DMDC and PDTC would have novel drug targets in 
Mycobacterium species. It is desirable that the antibacterial spectrum of OCT313HK is specific 
to slow growing mycobacteria, because of the mal-effect of long term therapy with anti-
tubercular drugs on an indigenous bacterial flora. Both OCT313 and OCT313HK are 
effective to multi drug resistance (MDR) including extremely multi drug resistance (XDR) of 
M. tuberculosis, thus, cross resistance with currently used anti-tubercular drugs. In the 
animal study using chronic infection model of tuberculosis, OCT313 reduced bacterial 
number in lung. The cytotoxicity of dithiocarbamates on human cell lines is reduced by 
conjugating to sugar. Therefore, sugar conjugated dithiocarbamates could be useful leading 
compounds to develop anti-mycobacterial drugs. 
3. Future view of sugar conjugated dithiocarbamates  
Nowadays, the proper usage of antibiotics and the drug dosage regimens following 
Pharmacokinetics / Pharmacodynamics (PK/PD) theory are emphasized on medication for 
infectious disease (Mouton et al., 2011; Vaddady et al., 2010). In the case of treatment of 
tuberculosis these consensuses are applicable. Furthermore, drug interaction with other 
medications should be a major concern at developing new drugs and usage of anti-TB 
drugs. As diarylquinoline TMC-207, an ATP synthase inhibitor, which was discovered by 
Tibotec, the drug metabolism catalyzed by CYP enzymes is also critical in the regimen 
(Matteelli, 2010). The excellent characters of the potential lung transfer, enhanced 
permeability and retention effect of drugs in lung are important factors for drugs late into 
anti-TB treatment. Dithiocarbamates have potentially inhibitory effect of both mammal and 
bacterial enzymes (Taylor et al., 1987; Shah et al., 1997; Kang et al., 2008; Erol et al., 1995; 
Cascio et al., 1996; Adachi et al., 1997; Nagano et al., 1997; Ohtake et al., 1998). Those are also 
effective to fungi (Le Quellec et al., 1996; Weuffen et al., 1967a, 1967b). It is very interesting 
to note that the drug target of DMDC or PDTC is changed when conjugated with GlcNAc. 
This is a very unique observation of sugar conjugated dithiocarbamates derivatives. Our 
preliminary studies indicated that OCT313 had post antibiotic effect on Mycobacterium, and 
the sufficient drug retention in the lung was observed. The effect of metabolic enzymes on 
OCT313 and OCT313HK is not known. The interaction of these drugs to other TB drugs 
including developing drugs should be investigated. Moreover, the route of administration is 
unclear. The innovation of rapid accumulation system to achieve the sufficient drug 
concentration in lung is also preferable. 
PDTC is also reported to have anti-viral activity against human immunodeficiency virus 
through inhibiting NF-B (Schreck et al. , 1992; Pande & Ramos , 2003; Bai  et al., 2008). 
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OCT313HK has not been investigated for the anti-viral effect on HIV. Possibly, sugar 
conjugated PDTC will be leading compounds for the treatment of both TB and AIDS. 
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